Basso Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Basso Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-119,539	Closed	-$1.18M	–	689
2022 Q1	$1.18M	Sell	119,539 -27	-0%	-$266	0.11%	283
2021 Q4	$1.18M	Sell	119,566 -28,138	-19%	-$276K	0.13%	238
2021 Q3	$1.44M	Buy	147,704 +4,193	+3%	+$40.6K	0.17%	204
2021 Q2	$1.39M	Buy	143,511 +66,661	+87%	+$648K	0.18%	195
2021 Q1	$747K	Buy	+76,850	New	+$744K	0.12%	204

Other funds holding BIOT

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Basso Capital Management's BIOT Position: Q2 2022 in Review

Basso Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q2 2022, closing a stake of 119,539 shares — an estimated $1.18M sold.

Basso Capital Management first reported a position in BIOT in Q1 2021 and held it in 5 quarters. The position peaked at $1.44M in Q3 2021. 67 funds tracked by Wall St. Rank hold BIOT as of Q2 2022.

Basso Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Basso Capital Management sold 119,539 Biotech Acquisition Company Class A Ordinary Shares shares in Q2 2022, an estimated $1.18M.
Basso Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 5 quarters.
Basso Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.44M in Q3 2021.
67 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q2 2022.

Based on Basso Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.